News
MEUSW
1.380
-10.39%
-0.160
PETROS PHARMACEUTICALS INC: NEW COLLABORATION WITH LEMONAID HEALTH
Reuters · 04/23 13:17
Column: Law firm Edelson pitches radical idea for picking lead in 23andMe case. Ask class members.
Alison Frankel: Law firm Edelson pitches radical idea for picking lead in 23andMe case. Frankel says plaintiffs have a say in picking lawyers to lead consolidated cases. She says firm hired professors to survey prospective class members about what they want. Franelson says class members want transparency, a quick settlement, a lean, efficient leadership team.
Reuters · 04/18 22:37
BUZZ-U.S. STOCKS ON THE MOVE-Ibotta, Blackstone, US health insurers
Wall Street's main stock indexes gained on Thursday. Dow Jones Industrial Average was up 0.11% at 37,793.34. Top three S&P 500 percentage gainers: Estee Lauder, United Airlines, Genuine Parts. Top two Nasdaq percentage losers: Las Vegas Sands and Tesla.
Reuters · 04/18 17:35
BUZZ-U.S. STOCKS ON THE MOVE-Ally Financial, Zscaler, Las Vegas Sands
Dow Jones Industrial Average was up 0.52% on Thursday. The benchmark S&P 500 and the Nasdaq were subdued as higher Treasury yields pressured equities. Zscaler, Las Vegas Sands, 23andMe and Ally Financial were among the day's top stocks.
Reuters · 04/18 16:32
BUZZ-Genetic testing firm 23andMe rises after CEO considers taking firm private
Genetic testing firm 23andMe's ME.O shares rise 40.3% to 50 cents. CEO Anne Wojcicki is considering making an offer to buy 23andme in a potential go-private transaction. Co says CEO owns more than 20% of company's outstanding shares.
Reuters · 04/18 14:26
23ANDME SHARES UP 24.9% AFTER CEO CONSIDERS TAKING FIRM PRIVATE
Reuters · 04/18 13:50
BUZZ-U.S. STOCKS ON THE MOVE-D.R. Horton, 23andMe, Copper miners
D.R. Horton, 23andMe, Copper miners rise as chip stocks rebound. Dow e-minis expected to open higher on Thursday. Investors await commentary from Federal Reserve officials on outlook for interest-rate cuts. 23andme rises after CEO considers taking firm private.
Reuters · 04/18 13:13
BUZZ-Genetic testing firm 23andMe extends gains after CEO considers taking firm private
Genetic testing firm 23andMe's ME.O shares extend gains to rise as much as 34.7% to $0.48 premarket. CEO Anne Wojcicki is considering taking firm private. Company says CEO owns more than 20% of the company's shares.
Reuters · 04/18 12:44
23ANDME HOLDING CO. - SPECIAL COMMITTEE WILL CAREFULLY REVIEW WOJCICKI'S PROPOSAL WHEN AND IF IT IS MADE AVAILABLE
Reuters · 04/18 12:00
23ANDME HOLDING CO. SHARES EXTEND GAINS PREMARKET, LAST UP 21.2%
Reuters · 04/18 11:47
BUZZ-23andMe rises after CEO considers taking firm private
Shares of genetic testing firm 23andMe rise 8.6% to 38 cents premarket. Firm's CEO Anne Wojcicki is considering making an offer to buy the company in a potential go-private deal. The company went public in 2021 through a deal backed by Richard Branson.
Reuters · 04/18 11:22
23ANDME HOLDING CO. SHARES UP 6.3% AT $0.38 PREMARKET AFTER FILING SHOWS CEO ANNE WOJCICKI CONSIDERING TAKING FIRM PRIVATE
Reuters · 04/18 11:07
PRESS DIGEST - Wall Street Journal - April 18
Google said it fired 28 employees who protested against the tech giant's contract with the Israeli government. Oracle plans to invest more than $8 billion in Japan over the decade. U.S. President Joe Biden called for raising tariffs on imports of steel and aluminum from China.
Reuters · 04/18 05:55
23andMe CEO Wojcicki considering taking firm private, filing shows
23andMe CEO Anne Wojcicki considering taking firm private, filing shows. 23andMe is best known for its saliva-based test kits that offer users glimpse into genetic ancestry. The company went public in 2021 in a deal valued at $3.5 billion.
Reuters · 04/18 02:57
23ANDME: ON APRIL 13 CEO WOJCICKI NOTIFIED SPECIAL COMMITTEE MEMBERS THAT SHE IS CONSIDERING MAKING PROPOSAL TO BUY CO IN GO-PRIVATE TRANSACTION
Reuters · 04/18 01:50
MEDIA-23andMe CEO Anne Wojcicki plans to take company private - WSJ
Reuters · 04/18 01:15
FACTBOX-Biggest cyberattacks in US healthcare sector
Biggest cyberattacks in U.S. Healthcare sector include Anthem, 23andMe. UnitedHealth Group's UNH.N hack adds to growing list of disruptive cyberattacks on healthcare companies. The biggest IT hacks in the sector affected more than 80,000 people.
Reuters · 03/20 13:20
23andMe Holding Co. reports results for the quarter ended in December - Earnings Summary
23andMe Holding Co. Reports results for the quarter ended in December. The company reported a quarterly adjusted loss of 16 cents per share. Revenue fell 33.2% to $44.75 million from a year ago. 23andMe shares had fallen by 20.7% this quarter.
Reuters · 02/08 07:42
MEDIA- 23andMe is exploring splitting the DNA company in two - Bloomberg News
Reuters · 02/07 19:28
23andMe Holding Co. <ME.OQ> expected to post a loss of 14 cents a share - Earnings Preview
23andMe Holding Co. expected to post a loss of 14 cents a share - Earnings Preview. The company is expected to show a fall in quarterly revenue when it reports results on February 7 for the period ending December 31 2023.
Reuters · 02/05 22:33
More
Webull provides a variety of real-time MEUSW stock news. You can receive the latest news about 23andMe Holding Co through multiple platforms. This information may help you make smarter investment decisions.
About MEUSW
23andMe Holding Co. is a genetics-led consumer healthcare and therapeutics company. The Company operates through two segments: Consumer & Research Services and Therapeutics. The Consumer & Research Services business segment comprises its Personal Genome Service (PGS), telehealth business, and research service. PGS services provide customers with a broad suite of genetic reports, including information on customers’ genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. The Therapeutics business segment focuses on the use of genetic insights from databases of genetic and phenotypic information to develop novel therapies to improve patients’ lives. The Therapeutics segment consists of out-licensing of intellectual property associated with identified drug targets and expenses related to therapeutic product candidates.